Therapeutic Drug Monitoring of Posaconazole in Hematology Patients: Experience with a New High-Performance Liquid Chromatography-Based Method-Reference-Cited by-同舟云学术

Therapeutic Drug Monitoring of Posaconazole in Hematology Patients: Experience with a New High-Performance Liquid Chromatography-Based Method

Published:2010-09 Issue:9 Volume:54 Page:4029-4032
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Neubauer Werner Christian¹²,Engelhardt Monika¹,König Armin³,Hieke Stefanie⁴,Jung Manfred⁵,Bertz Hartmut¹,Kümmerer Klaus³

Affiliation:

1. Department of Hematology & Oncology

2. Hospital Pharmacy

3. Department of Environmental Health Sciences

4. Institute of Medical Biometry and Medical Informatics, University Medical Center Freiburg

5. Institute of Pharmaceutical Sciences, University of Freiburg, Freiburg, Germany

Abstract

ABSTRACT Parallel administration of the proton pump inhibitor (PPI) esomeprazole has been shown to decrease oral bioavailability of posaconazole in healthy volunteers. We prospectively analyzed serum samples ( n = 59) obtained from hematology patients ( n = 27) under posaconazole prophylaxis. Patients treated concomitantly with pantoprazole had significantly lower posaconazole levels than patients without PPI treatment (median levels of 630 μg/liter versus 1,125 μg/liter, respectively). These results suggest that drug monitoring is relevant when posaconazole and pantoprazole are administered concomitantly.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00150-10

Reference28 articles.

1. Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications

2. Pharmacokinetics, Safety, and Tolerability of Oral Posaconazole Administered in Single and Multiple Doses in Healthy Adults

3. Courtney, R., D. Wexler, E. Radwanski, J. Lim, and M. Laughlin. 2003. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Antimicrob. Agents Chemother.57:218-222.

4. 42nd Intersci. Conf. Antimicrob. Agents Chemother. 2002

5. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Prospective Study to Evaluate the Effect of Therapeutic Drug Monitoring-Based Posaconazole Prophylaxis on Invasive Fungal Infection Rate During Acute Myeloid Leukemia Induction Therapy;Indian Journal of Hematology and Blood Transfusion;2023-10-29

2. Exposure-Response Relationship of Posaconazole Suspension in Theprophylaxis of Invasive Fungal Infections in Patients with Acute Myeloid Leukemia;Indian Journal of Hematology and Blood Transfusion;2022-09-05

3. Antifungal prophylactic effectiveness and intrapulmonary concentrations of voriconazole versus posaconazole in lung transplant recipients;Medical Mycology;2022-08-29

4. Pharmacokinetics and Pharmacodynamics of Posaconazole;Drugs;2020-04-22

5. Efficacy of Posaconazole Prophylaxis for Fungal Disease in Hematology Patients Treated With Chemotherapy and Transplantation: An Open-Label, Prospective, Observational Study;Frontiers in Microbiology;2020-03-19